Skye Bioscience, Inc.
SKYE
$3.29
-$0.26-7.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -123.02% | -121.20% | -120.51% | 84.37% | -153.99% |
| Total Depreciation and Amortization | 527.85% | 542.75% | 517.25% | 129.17% | -12.09% |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | 8.89% | -- |
| Total Other Non-Cash Items | -6.79% | 65.18% | 427.45% | -112.29% | 1,465.54% |
| Change in Net Operating Assets | 405.12% | 64.13% | -686.08% | 282.91% | -263.37% |
| Cash from Operations | -51.49% | -95.10% | -112.58% | -29.79% | -256.14% |
| Capital Expenditure | 100.00% | -96.88% | -614.29% | -40,937.84% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -36,376.92% | -1,221.63% | 1,391.43% | -234.70% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 2,329.31% | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -2,327.16% | -- | -- |
| Cash from Financing | 100.87% | -- | 124.67% | -100.00% | -1,598.62% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -144.88% | -126.79% | -108.47% | -149.13% | -335.99% |